Language
European Parliament
Every sitting is free to watch on Polyfact, live and on replay, no account needed.
Latest update yesterday
What is said in the sittings, update by update, the latest first. Each update opens the video at the second it was said.
Final interventions highlight responsibilities in an ageing society, the need to defend evidence‑based medicine and vaccine confidence against denialism, and consolidate priorities on capacity, workforce support, continuity of care and strengthened interparliamentary cooperation to build a more resilient European health union.
Adam Jarubas and 4 others
The second session focuses on national resilience strategies, legal frameworks and EU support, then broadens to expert assessments of cross‑European resilience gaps and trust deficits, before examining long‑term impacts such as deferred care, chronic disease, long COVID, workforce constraints and the need to protect continuity of care and vaccine confidence.
In this chapter
Adam Jarubas and 9 others
National parliamentarians, MEPs, HERA and experts engage in a joint debate on governance of emergency powers, civil liberties, proportionality of COVID‑19 measures, misinformation, industrial policy and joint procurement, leading to calls for stronger EU‑level coordination, permanent solidarity mechanisms, extended joint procurement, and interoperable data and pathogen‑surveillance infrastructures.
In this chapter
Introductory statements frame the interparliamentary meeting’s objectives on COVID‑19 lessons and future preparedness, followed by HERA’s presentation of the reinforced EU health security architecture, national experiences from Sweden and Italy, scientific warnings on denialism, AI‑driven biothreats and pathogen data governance, and hospital‑level reforms for organisational resilience.
In this chapter
Committee on Public Health Ordinary meeting
ECDC’s Director briefs on the Ebola outbreak in Africa and record West Nile spread in Europe, outlining risks, preparedness and One Health needs; MEPs then question her on global health funding, vaccine development, blood safety, climate impacts, airport controls and health‑workforce protection, with detailed responses on vaccine pipelines, SoHO guidance, climate‑linked surveillance, cooperation with WHO and Africa CDC, and the severity and long‑term effects of West Nile, before the Chair closes the meeting.
In this chapter
Committee on Public Health Ordinary meeting
The Chair closes the biotech debate, introduces the committee’s ECDC visit, hears Catarina Martins’ report on ECDC’s mandate and resource needs, and formally adopts the mission report while launching the subsequent exchange with the ECDC Director on Ebola and West Nile.
In this chapter
Committee on Public Health Ordinary meeting
Professor Forte and patient advocate Drachmann call for a pan‑European framework on funding, GMO rules, EMA expertise and centres of excellence, illustrate systemic delays through a rare‑disease gene‑therapy case, and link needs to the Biotech Act, followed by an MEP debate on market fragmentation, regulatory obstacles, Council resistance and EU–US–China cooperation, with replies stressing a unified market, risk‑adapted regulation and cross‑border trial networks.
In this chapter
Committee on Public Health Ordinary meeting
Rapporteur and MEPs question experts on the impact of SPCs on hospital ATMP development, the limits of joint clinical assessment and early access schemes, barriers to scaling hospital exemption models and cross‑border CAR‑T, and reimbursement bottlenecks, while experts respond on SmPC constraints, hospital–industry collaboration, IITs and cross‑border legal use of hospital exemption.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the hearing on advanced therapy medicinal products and the first expert and Lithuanian clinicians outline EU access gaps, fast‑track needs and the hospital exemption CAR‑T model for small Member States, including reimbursement disparities, cross‑border treatment, regulatory standards and sustainability requests to Parliament.
In this chapter
Committee on Public Health Ordinary meeting
MEPs raise taxation and food policy, EU‑wide screening, rural access, school exercise, industry regulation and national performance, prompting expert discussion of population‑level screening using glucose and HbA1c, social determinants and inequalities in access to new drugs, stigma and blame narratives around type 2 diabetes, the need for integrated care pathways, and full inclusion of children with diabetes in physical activity, before the Chair closes the session and promotes on‑site testing.
In this chapter
Committee on Public Health Ordinary meeting
The Chair closes the gender item, opens the agenda point on early action on diabetes and introduces experts, who set out IDF Europe’s prevention and physical activity agenda, Erasmus+ tools, and the epidemiology, costs and mortality of diabetes in Europe, distinguishing type 1 from type 2 and underlining early detection, lifestyle measures and modern cardio‑protective treatments.
In this chapter
Committee on Public Health Ordinary meeting
Experts respond on EU frameworks and Biotech Act implementation, obstetric and gynaecological violence, national best practices, and the neglect of endometriosis, while stressing the central role of prevention, HPV vaccination and screening, the need to include women (including pregnant women) in trials, to adjust pharma incentives, and to scale up EU funding and awareness for women’s specific conditions.
In this chapter
Committee on Public Health Ordinary meeting
The rapporteur and several MEPs highlight persistent discrimination in women’s health, underrepresentation in research, gaps on fertility, prenatal care and endometriosis, and call for an EU strategy on gender and health, while asking experts about frontrunner member states, informed consent, and concrete priorities and legislative levers at EU level.
In this chapter
Committee on Public Health Ordinary meeting
EIGE’s expert links unequal health prevention and outcomes to broader structural gender inequalities, intersectional disadvantages and gaps in screening and diagnosis, then identifies EU priorities around supporting informal carers, investing in quality care services, and promoting positive gender norms to improve prevention and reduce violence against women.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the SANT meeting, sets the agenda on gender inequalities in health, and introduces ESGO’s expert, who outlines the burden of gynaecological cancers, structural research gaps, and gender bias in trials before presenting concrete ESGO asks for EU-level instruments, including ring‑fenced funding, Biotech Act implementation with sex‑disaggregated data, centres of excellence, and an EU women’s health plan.
In this chapter
Committee on Public Health Ordinary meeting
MEPs and the rapporteur question experts on COVID isolation impacts, prevention campaigns, ECT, substance use, PTSD, deinstitutionalisation, system design and financing responsibilities, leading to calls for integrated brain‑health approaches, community‑based and culturally appropriate services, and sustained national commitment backed by EU pilots. The rapporteur invites further written input for the INI report, announces follow‑up materials and formally closes the SANT committee meeting.
In this chapter
Committee on Public Health Ordinary meeting
The rapporteur opens the youth mental health workshop and three experts present clinical, public‑health and youth perspectives on rising mental disorders and suicide, risk factors across the life course, digital risks, and evidence‑based interventions. They advocate community‑based youth hubs, cross‑sector policies, regulation of digital determinants, and meaningful youth participation in service design and standards.
In this chapter
Committee on Public Health Ordinary meeting
The committee examines oral questions on how US pharmaceutical pricing policies affect EU medicine access, with Stine Bosse warning of launch and pricing risks and urging stronger EU coordination on pricing and HTA. Members then run a test vote, adopt the oral questions to the Commission and Council, and close the voting block.
Committee on Public Health Ordinary meeting
The chair introduces a study on AI in public health and Daniela Spajic maps how GDPR, the Data Governance Act, the European Health Data Space, the AI Act and the Digital Omnibus shape use of health data for AI. MEPs question her on EHDS opt‑out, privacy, security, AI reliability, medical secrecy and liability, and she clarifies data subjects’ rights, secure processing environments, the role of intermediaries and the requirement for human oversight, before the chair closes the item.
In this chapter
Committee on Public Health Ordinary meeting
The chair opens the SANT committee meeting, adopts the agenda and sets out the pharma package second‑reading procedure, then WHO details the Irkutsk lab worker pneumonia case and explains IHR‑based verification. Coordinators and WHO exchange on biosafety, Russian data reliability, disinformation, gain‑of‑function research, and reforms to the IHR and a future pandemic accord, clarifying WHO’s mandate and limits.
In this chapter
Committee on Public Health Ordinary meeting
The Chair organises the voting block, with rapporteurs González Casares and Voiculescu presenting the European rare diseases action plan and the Europe’s Beating Cancer Plan implementation report, after which the committee votes on compromise amendments and adopts both texts by roll call before the Chair closes the meeting and announces the next session and a coordinators’ follow‑up.
In this chapter
Committee on Public Health Ordinary meeting
Alba Gil outlines the cancer burden, key risk factors and EU single‑market levers for prevention, while Gianluigi Giannelli presents obesity data, the economic case for structured lifestyle programmes and the Mediterranean diet, followed by MEPs’ questions on EU‑wide prevention strategy, labelling, advertising, taxation and equity, and closing replies stressing healthier food and alcohol environments, early‑life interventions, support for low‑income groups and stronger tobacco and alcohol risk messaging.
In this chapter
Committee on Public Health Ordinary meeting
The Chair launches the public hearing on healthy lifestyles, with Milena Simeoni advocating systemic, underfunded lifestyle‑based health promotion and a new practitioner profile, and Robert Barouki detailing the exposome, lifestyle determinants and persistent health inequalities, after which MEPs and experts exchange on an EU lifestyle strategy, fiscal tools, new professional roles, structural determinants and training needs, including calls for large exposome cohorts and competence‑based approaches to behaviour‑change support.
In this chapter
Committee on Public Health Ordinary meeting
Committee coordinators and additional MEPs question Commissioner Várhelyi on concrete EU financing and instruments for CVD prevention, implementation gaps, vaccination guidance, health data and e‑cigarette regulation, prompting detailed replies on rebalancing health budgets towards prevention, use of EU funds, upcoming Council recommendations, EMA vaccine safety findings and future tobacco and vaccination proposals, followed by a political clash over vaccine narratives and disclosure of Safe Hearts and health funding before the Chair closes the item.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the SANT committee meeting, adopts the agenda and minutes, links the session to World Heart Day, and gives the floor to Commissioner Várhelyi to present the Safe Hearts Plan, its 2035 CVD mortality target, legislative links (tobacco, vaping, medical devices, biotech) and the new Council recommendation on cardiovascular health checks and EU Screening Week.
In this chapter
Committee on Public Health Ordinary meeting
A further exchange focuses on whether company resistance is blocking progress, expectations for binding donation commitments, WHO neutrality and communication to rebuild public trust in the treaty, before the Chair concludes by stressing stronger WHO cooperation and formally adjourns the meeting.
In this chapter
Committee on Public Health Ordinary meeting
MEPs question the EU delegate on leadership, Africa partnerships, IP and equitable access, prompting explanations of why biodiversity-style ABS is unsuitable for pathogens, how it is stalling the overall agreement, and how private-law contracts for in-kind company donations could strengthen WHO’s role without transactional pathogen leverage.
In this chapter
Committee on Public Health Ordinary meeting
The EU delegate presents the background, objectives and architecture of the WHO pandemic agreement and its PABS annex, then details geopolitical divisions over access and binding benefit sharing that delay entry into force and drive the search for workable compromises.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the SANT meeting, adopts the agenda and minutes, holds the vote on the draft opinion on the 2027 EU general budget, and then introduces the WHO pandemic agreement’s PABS annex, the EU delegate and the planned hearing format.
In this chapter
Committee on Public Health Ordinary meeting
IMEC presents its TechBio and AI‑enabled drug discovery vision, highlighting data and infrastructure needs, followed by MEP questions on patents, the European Health Data Space, data governance, bias and safety, before the Chair closes the meeting.
In this chapter
The search covers the sittings held more than two weeks ago. A Polyfact subscription searches every sitting as soon as it is transcribed.
European Parliament broadcasts the sittings of the Committee on Public Health (SANT). Polyfact shows each one live, keeps it as a replay with its transcript and links its key moments to the second they were said.
47 sittings on Polyfact since 14 May 2025
Polyfact records and transcribes the sittings and committee hearings of European Union's parliaments. A speaker is named only once their identity is confirmed, by the official record or by a person; automatic guesses are left out.
On Polyfact, free and without an account: a sitting on air is marked live in the schedule above, and each sitting stays available as a replay.
Yes. Watching the sittings on Polyfact is free and needs no account. A Polyfact subscription, which you can try for free, adds the full transcripts as soon as they are ready, search across every sitting and alerts on your topics.
On each sitting's page on Polyfact, speaker by speaker, with its key moments one click from the second they were said. The search on this page covers the sittings held more than two weeks ago.
With a Polyfact plan you read every sitting as soon as it is transcribed, ask questions to the video assistant and get an alert as soon as your topics come up.
14-day free trial. A card is required, nothing is charged for 14 days, and you can cancel anytime.
Updated
'%20d='m0%200%2016%2011h61%2061%2061%2061%2060L47%2037h61%2061%2060%2061L16%2063h61%2061%2061%2061%2060L47%2089h61%2061%2060%2061L16%20115h61%2061%2061%2061%2060L47%20141h61%2061%2060%2061L16%20166h61%2061%2061%2061%2060L47%20192h61%2061%2060%2061L16%20218h61%2061%2061%2061%2060z'/%3e%3c/svg%3e)
